title: Severe HIV-associated hypertriglyceridaemia treated with rosuvastatin plus omega-3 fatty acids.
abstract: Compared with healthy controls, HIV patients already have abnormal lipoprotein concentrations before the initiation of highly active antiretroviral therapy (HAART), which worsen with the therapy. HAART-associated dyslipidaemia features fundamental proatherogenic changes such as increased plasma triglycerides (TGs), increased total cholesterol and low-density lipoprotein cholesterol as well as decreased high-density lipoprotein cholesterol (HDL-C). The current guidelines for managing HIV-associated dyslipidaemia recommend diet and exercise counselling, alteration of HAART regimen or addition of lipid-lowering medications such as statins, fibrates and omega-3 (OM-3) fatty acids. Given that cardiovascular risk significantly increases with elevated lipid levels, selecting a drug to manage dyslipidaemia is particularly important. A case is described of an HIV patient who had severe hypertriglyceridaemia and bad metabolic parameters treated with rosuvastatin and OM-3 fatty acids. So we obtained a more marked reduction of TG levels than has never been described before in the literature, associated with a significant increase in HDL-C levels.
authors.affiliation: Infectious Diseases Clinic, Department of Medicine and Aging, 'G. d'Annunzio' University, Chieti, Italy.
authors.forename: K
authors.initials: K
authors.lastname: Falasca
authors.forename: C
authors.initials: C
authors.lastname: Ucciferri
authors.forename: P
authors.initials: P
authors.lastname: Mancino
authors.forename: E
authors.initials: E
authors.lastname: Pizzigallo
authors.forename: L
authors.initials: L
authors.lastname: Calza
authors.forename: J
authors.initials: J
authors.lastname: Vecchiet
mesh_terms: D000328:Adult; D004359:Drug Therapy, Combination; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005464:Fluorobenzenes / Q000008:administration & dosage*; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D015228:Hypertriglyceridemia / Q000188:drug therapy*; D008297:Male; D011743:Pyrimidines / Q000008:administration & dosage*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000008:administration & dosage*
chemical_list: D015525:Fatty Acids, Omega-3; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium